Multiple Sclerosis

The AJMC® Multiple Sclerosis compendium is a comprehensive resource for clinical news and expert insights for the disabling disease that impacts the brain and spinal cord.

Latest News

man with mulitple sclerosis and walker | Image credit: chartphoto - stock.adobe.com
The Rise of Precision Monoclonal Antibodies in Treating MS

July 7th 2025

Advancements in B-cell therapies, including anti-CD20 and anti-CD19 monoclonal antibodies, enhance treatment efficacy and safety for multiple sclerosis and autoimmune diseases.

The MUSETTE trial did not meet its primary end point, suggesting a higher dose of IV ocrelizumab does not provide added benefits compared with the currently approved 600 mg dose. | Image credit: Chanintorn.v - stock.adobe.com
Higher-Dose Ocrelizumab Shows No Added Benefit vs Approved Dose in MS

April 9th 2025

MS wordcloud | Image Credit: © arloo-stock.adobe.com
5 Ongoing Clinical Trials Evaluating Treatment for MS

March 14th 2025

Kavita Nair Q&A - Maks_Lab - stock.adobe.com.jpeg
Coming Together to Ensure Neurological Treatment Access: Q&A With Kavita V. Nair, PhD

March 12th 2025

Ocrelizumab is approved as an IV infusion for relapsing and primary progressive forms of MS and as a subcutaneous injection, given twice a year. | Image credit: Trsakaoe - stock.adobe.com
Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials

January 9th 2025

Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain key insights into managing and understanding this condition.

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain valuable insights into managing and understanding this complex condition.
Continuing Medical Education
View All
July 8th 2025

The Role of the Specialty Pharmacist in Optimizing Treatment for Amyotrophic Lateral Sclerosis: The Impact of Early Intervention, Patient-Centered Care, and Disease-Modifying Therapies in Slowing Disease Progression

1.0 Credit / Neurology
July 8th 2025

Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis

1.0 Credit / Immunology, Neurology
July 8th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 8th 2025

Overview and Burden of Migraine

0.5 Credit / Neurology
July 8th 2025

The Role of the Pharmacist Migraine Management

0.5 Credit / Neurology
July 8th 2025

The Evolving Treatment Landscape of Migraine

0.5 Credit / Neurology
July 8th 2025

Leveraging Managed Care to Optimize Patient Outcomes: Integrating Novel Treatments in Schizophrenia

1.5 Credits / Neurology, Psychiatry
July 8th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Improving Patient-Clinician Communication and Treatment Adherence
September 12th 2014

Improving Patient-Clinician Communication and Treatment Adherence

Laura Joszt, MA
Although there have been significant advances in multiple sclerosis management, patient preferences need to be taken into account before choosing treatment, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.
Engaging Patients in Their Own Treatment Decisions
September 12th 2014

Engaging Patients in Their Own Treatment Decisions

Laura Joszt, MA
Patients with multiple sclerosis want to be actively engaged in their treatment decisions, which will help their long-term health and medication adherence, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.
Heterogeneity of MS Makes New Disease Biomarker Discovery Difficult
September 12th 2014

Heterogeneity of MS Makes New Disease Biomarker Discovery Difficult

Laura Joszt, MA
The treatment landscape for multiple sclerosis continues to get more complex month to month, which makes biomarker discovery increasingly important for treating the disease, said Suhayl Dhib-Jalbut, MD, professor at the Rutgers University Robert Wood Johnson Medical School, during his session at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts.
PML is Treatable in MS, but Long-Term Function Can Remain Affected
September 11th 2014

PML is Treatable in MS, but Long-Term Function Can Remain Affected

Laura Joszt, MA
Although the survival rate of natalizumab-associated progressive multifocal leukoencephalopathy (PML) is better than PML in HIV patients, long-term they may need some assistance and care, Ralf Gold, Ruhr University Bochum in Germany, said at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts.
Using Advanced Imaging Techniques to Better Understand MS Progression
September 11th 2014

Using Advanced Imaging Techniques to Better Understand MS Progression

Laura Joszt, MA
Advanced imaging techniques are becoming necessary to further understanding of the progression of multiple sclerosis, according to presenters at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts, from September 10-13.
Collaborative Decision Making Tops Efficacy for MS Patients
September 11th 2014

Collaborative Decision Making Tops Efficacy for MS Patients

Laura Joszt, MA
When choosing treatment for a patient, whether he or she has a clinically isolated syndrome or clinically definite multiple sclerosis, providers need to establish a collaborative relationship, according to speakers at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts.
Site Logo
April 16th 2014

The Burden of Soaring Prices of Specialty Drugs

Even as the cost of prescription drugs has plummeted for many Americans, a small slice of the population is being asked to shoulder more and more of the cost of expensive treatments for diseases like cancer and hepatitis C, according to a report to be released on Tuesday by a major drug research firm.
Site Logo
March 3rd 2014

Chronically Ill Face High Out-of-Pocket Costs

Katie Sullivan
Those with chronic illnesses such as leukemia, hepatitis C, and multiple sclerosis may face a significant increase in their out-of-pocket expenses for specialty drugs. This is because payers are replacing fixed-dollar copayments with coinsurance rates that require patients to contribute a higher percentage of the cost for their specialty medications.
Site Logo
February 4th 2014

Pharmacy Benefit Management Institute Conference Highlights

Katie Sullivan
This week AJMC is covering session highlights from the PBMI Annual Drug Benefit conference.
Site Logo
November 30th 2013

Impact of Diagnosis and Early Treatment on the Course of Multiple Sclerosis

Katia Noyes, PhD, MPH Bianca Weinstock-Guttman, MD
Site Logo
November 30th 2013

Choosing the Best Treatment for Multiple Sclerosis: Comparative Effectiveness, Safety, and Other Factors Involved in Disease-Modifying Therapy Choice

Laura E. Happe, PharmD, MPH
Site Logo
November 30th 2013

An Update on New and Emerging Therapies for Relapsing-Remitting Multiple Sclerosis

Bianca Weinstock-Guttman, MD
Site Logo
November 30th 2013

Participating Faculty: Current Topics in Multiple Sclerosis

Site Logo
November 29th 2013

Post Test: A Data-Driven Approach to Improving Clinical and Economic Outcomes in Multiple Sclerosis

Site Logo
November 26th 2013

Managed Care Aspects of Managing Multiple Sclerosis

Gary M. Owens, MD
Site Logo
November 25th 2013

Management of Multiple Sclerosis

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Site Logo
November 24th 2013

Participating Faculty: A Data-Driven Approach to Improving Clinical and Economic Outcomes in Multiple Sclerosis

Site Logo
November 24th 2013

Multiple Sclerosis Update

Clyde E. Markowitz, MD
Patricia Coyle, MD, Discusses Treatment of Multiple Sclerosis
October 29th 2013

Patricia Coyle, MD, Discusses Treatment of Multiple Sclerosis

Patricia Coyle, MD, director, MS Comprehensive Care Center, Stony Brook Neurosciences Institute, professor and vice chair of clinical affairs, Department of Neurology, SUNY at Stony Brook, says that prognostically, the earlier you treat multiple sclerosis the better.
Strengthening the Assessment of Long-Term Treatment Outcomes in MS
October 4th 2013

Strengthening the Assessment of Long-Term Treatment Outcomes in MS

The gold standard for measuring treatment outcomes in multiple sclerosis (MS) is the randomized clinical trial (RCT). However, RCTs are often short-sighted and biased in their execution. Dr Maria Sormani, PhD, Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy, addressed this problem in a lecture on immunomodulatory treatment of MS.
Fred Lublin, MD, Examines Research and Key Takeaways from ECTRIMS 2013
October 4th 2013

Fred Lublin, MD, Examines Research and Key Takeaways from ECTRIMS 2013

In this video, Fred Lublin, MD, Saunders Family professor of neurology, director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, discussed the results of his poster presentation, Natalizumab Reduces the Disabling Amplitude of Multiple Sclerosis Relapses and Improves Post-relapse Residual Disability.
A Look at the Widespread Economic Burden of Multiple Sclerosis
October 4th 2013

A Look at the Widespread Economic Burden of Multiple Sclerosis

Clinical trials and treatment in multiple sclerosis (MS) place an unwelcome economic burden upon countries with MS prevalence. With rising costs and a growing interest in MS clinical trials from emerging countries, new studies are needed to evaluate the significance of these factors.
Fatigue and Cognitive Impairment in Multiple Sclerosis
October 4th 2013

Fatigue and Cognitive Impairment in Multiple Sclerosis

Fatigue and cognitive impairment are 2 of the most common health problems associated with multiple sclerosis (MS). Recent MS studies evaluate the nature of these 2 conditions not just as side effects of MS, but as chronic conditions with varying degrees of severity based on objective assessment and self-perception.
Barry Singer, MD, Answers how the ACA will affect MS Patients
October 4th 2013

Barry Singer, MD, Answers how the ACA will affect MS Patients

Barry Singer, MD, director, MS Center for Innovations in Care, St. Louis, MO, said that the Affordable Care Act could cause challenges in terms of coverage.
Tecfidera and Ampyra Show Potential for Quality-of-Life Improvement in Patients With MS
October 4th 2013

Tecfidera and Ampyra Show Potential for Quality-of-Life Improvement in Patients With MS

New disease-modifying drugs in multiple sclerosis (MS) show potential for improving quality-of-life (QoL) of patients with multiple sclerosis. The clinical benefits of dimethyl fumarate and PR-fampridine were discussed at a Biogen Idec-sponsored satellite symposium at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
Daniel Kantor, MD, Addresses Risk Management in New Multiple Sclerosis Agents
October 3rd 2013

Daniel Kantor, MD, Addresses Risk Management in New Multiple Sclerosis Agents

Daniel Kantor, MD, medical director, Neurologique, immediate past president, Florida Society of Neurology, said that after an initial diagnosis of multiple sclerosis (MS) is made, providers must compare risks versus benefits when choosing which agent to treat with.
The Place of Genetics in MS Research
October 3rd 2013

The Place of Genetics in MS Research

Recent discussions of risk gene variation and pharmacogenitc studies were highlighted at a parallel session during the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Genome-Wide Association Studies (GWAS) have identified over 100 common risk variants in just over a quarter of observed heritability.
The Probability of Early Prediction in MS Disease Activity
October 3rd 2013

The Probability of Early Prediction in MS Disease Activity

Predictors of long-term disability and treatment failure in multiple sclerosis were discussed at a platform presentation during the 29th Congress European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). In the first presentation discussed here, Marzia Romeo, MD, San Raffaele Hospital, Milan, Italy, shared findings from an observational study examining the viability of early prediction of long-term treatment failure in relapsing remitting multiple sclerosis (RRMS) patients treated with disease-modifying treatments (DMT).
Recent studies in the uses of Natalizumab and Peginterferon Beta-1a to Treat Relapsing-Remitting Multiple Sclerosis
October 3rd 2013

Recent studies in the uses of Natalizumab and Peginterferon Beta-1a to Treat Relapsing-Remitting Multiple Sclerosis

At a satellite symposium during the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference, presenters focused upon the usage of disease-modifying treatments (DMT) in relapsing-remitting multiple sclerosis (RRMS).
Self-Reporting in MS: Bridging the Knowledge Gap Between Patients and Physicians
October 3rd 2013

Self-Reporting in MS: Bridging the Knowledge Gap Between Patients and Physicians

Self-reporting among multiple sclerosis (MS) patients was the focus of 2 posters during a Quality of Life (QoL) poster session at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
<1
...
1415161718192021>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo